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                      ABSTRACT 
 
BACKGROUND: 
       Hepatic encephalopathy is the 
commonest complication of cirrhosis. In 
patients with cirrhosis a spectrum of neuro 
psychiatric abnormalities exist ranging from 
indiscriminable changes in cognition(MHE) 
to clinically obvious changers in intellect, 
behavior, motor functions and 
consciousness(overt HE) 
AIM: 
     To detect minimal hepatic 
encephalopathy in cirrhotic patients in 
south indian population using PHES. 
 
 
METHODS: 
      In this study 40 cases and 40 controls 
were taken. Cases are cirrhotic patients 
without obvious neurological findings. 
PHES score includes NCTA,NCTB, 
DST,LDT,CDT. 
RESULTS: 
      Out of the 40 patients 19 cases(47.5% 
are found to have MHE 
CONCLUSION: 
     PHES is statistically significant in 
detecting MHE in cirrhotic patients. 
KEYWORDS: 
   Hepatic encephalopathy 
   Minimal hepatic encephalopathy  
 Psychometric hepaticencephalopathy score 
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INTRODUCTION 
Hepatic encephalopathy is the commonest complication of 
cirrhosis.in patients with cirrhosis,a spectrum of neuropsychiatric 
abnormalities exist ranging from clinically indiscernible changes in 
cognition(MHE) to clinically obvious changes in intellect, behavior, 
motor function and consciousness.(overt HE) .most common precipitating 
factors for HE are sepsis, gastrointestinal hemorrhage, constipation, 
dehydration, uremia, hypokalemia, alkalosis. 
MHE is used to describe patients with cirrhosis who are clinically 
normal but who show abnormalities of cognition and neurophysiological 
variables. 
MHE – detrimental effect on HRQOL. 
          -ability to perform complex tasks such as driving. 
          -increases the risk of developing overt HE. 
         -early identification – improves HRQOL and prognosis. 
Inflammation and raised serum ammonia levels is the main pathogenic 
factors for HE. 
 
 
  
 
 
 
 
AIMS & OBJECTIVES 
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AIMS AND OBJECTIVES 
 
 To standardize the PHES  in healthy south Indian population and 
evaluate the prevalence of MHE among south Indian patients with 
liver cirrhosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW 
 OF  
LITERATURE 
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REVIEW OF LITERATURE 
Weight of normal adult liver is 1400 to 1600 grams. Approximately 2.5% 
of body weight. Cirrhosis is the twelfth leading cause of death in US, and 
its burden is increasing worldwide. The term cirrhosis is derived from 
Greek medicine meaning orange yellow color of diseased liver. Cirrhosis 
is caused by many etiologies like alcoholic , viral hepatitis, metabolic, 
drugs, cardiac causes, etc. 
 Cirrhosis is defined by three morphologic features. 
1- Bridging fibrous septa- linking portal tract with one another and 
portal tract with terminal hepatic veins. 
2-parenchymal nodules-hepatocyte encircled by fibrosis. 
3-disruption of liver architecture. 
Up to forty percentage of patients with cirrhosis were asymptomatic until 
the occurrence of decompensation in the form of bleeding varices, 
spontaneous bacterial peritonitis and hepatic encephalopathy, previously 
cirrhosis and fibrosis was thought to be irreversible but new evidence 
says that fibrosis may be reversible in some alcoholics after abstaining 
and in some chronic hepatitis b and hemochromatosis patients. 
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PATHOGENESIS 
The main pathogenic process in cirrhosis is 
1- Death of hepatocyte 
2- Extracellular matrix deposition 
3-vascular regeneration. 
Proliferation of hepatic cells and their activation into highly fibrogenic 
cells is the main mechanism of fibrosis.  
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RISK FACTORS: 
Heavy alcohol consumption 
Health care professionals 
Obesity 
Tattooing 
Unprotected sex 
Toxic and chemical exposures 
Certain medications 
IV drug abusers sharing intravenous needles 
ETIOLOGY: 
Alcoholic liver disease 
Viral: 
 Chronic hepatitis C 
 Chronic hepatitis B 
 Cytomegalovirus 
 Epstein Barr virus 
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Metabolic: 
 NAFLD/NASH 
 Hemochromatosis 
 Wilson’s disease 
 Diabetes mellitus 
 Alpha 1 anti-trypsin deficiency 
 Cystic fibrosis 
 Tyrosinosis 
 Hereditary fructose intolerance 
 Glycogen storage diseases 
Drug induced: 
 Amiodarone 
 Methotrexate 
 Nitrofurantoin 
Biliary cirrhosis 
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 Primary biliary cirrhosis 
 Primary sclerosing cholangitis 
 Autoimmune cholangiopathy 
Cardiac: 
 Chronic right heart failure 
 Tricuspid regurgitation 
Cryptogenic 
 
CLINICAL FEATURES: 
Patient with chronic liver disease may be identified in the following ways
 
(3)
: 
1. Patients may be identified on routine clinical examination. 
2. They might have undergone laboratory/radiological imaging or 
some procedures which incidentally found out the presence of 
chronic liver disease. 
3. They may present in a decompensated state. 
4. Some patients may never come to clinical attention.(4) 
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HISTORY: 
This should include questions to identify risk factors for chronic liver 
disease like history of alcohol intake, hepatitis, jaundice, diabetes, illicit 
drug use, blood transfusion, any surgery, family history of liver diseases 
and autoimmune conditions. 
Questioning should also include those related to symptoms of chronic 
liver disease like fatigue, pedal edema, weight loss, confusion, bleeding 
tendency. 
Symptoms may vary from asymptomatic to overt features of 
decompensation. Patients with chronic liver disease due to hepatitis C 
may have muscle wasting, large ascites and overt hepatic encephalopathy 
but only mild jaundice while patients with chronic liver disease due to 
primary biliary cirrhosis may have deep icterus but no muscle wasting. 
Patients may experience fatigue, anorexia, weight loss. Cutaneous 
manifestations may include jaundice, spider naevi, paper money skin, 
palmar erythema, white nails, disappearance of lunulae, and finger 
clubbing. 
Increased conversion of androgens to estrogen occurs in adipose tissue, 
skeletal muscle which may be responsible for loss of axillary and pubic 
hair, gynecomastia, and impotence. Anemia may be due to folate 
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deficiency, hemolysis, and hypersplenism. Thrombocytopenia is usually 
the first marker of hypersplenism. Coagulopathy results from decreased 
production of coagulation factors and diminished absorption of vitamin  
SYMPTOMS: 
 Fatigue, weakness 
 Poor appetite 
 Muscle wasting 
 Jaundice 
 Breast enlargement in men 
 Ascites 
 Parotid gland enlargement 
 Altered sleep pattern, somnolence, 
Pruritus 
Blood vomiting 
 Redness of palms 
 Impotence, loss of libido 
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SIGNS 
Signs may be classified as those associated with etiology and those 
associated with decompensation. 
SIGNS ASSOCIATED WITH ETIOLOGY: 
Alcohol related: 
 Parotid enlargement 
 Dupuytren’s contracture 
 Peripheral neuropathy 
 Cerebellar signs 
 Testicular atrophy 
Wilson’s disease: 
 Kayer Fleischer ring 
 Hepatomegaly 
 Dystonia, tremors, involuntary movements 
Hemochromatosis: 
 Increased pigmentation 
 Hepatomegaly 
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NASH: 
 Xanthomas, xanthelesma 
 Corneal arcus 
Viral hepatitis: 
 Tattoo marks, injection marks 
Right heart failure: 
 Peripheral edema 
 Elevated JVP 
SIGNS OF DECOMPENSATION: 
 Icterus 
 Ascites  
 Peripheral edema 
 Ecchymosis 
 Asterixis 
 Encephalopathy 
 Bleeding varices 
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 Spider angiomata 
 Cruveilheir Baumgarten murmur 
 Fetor hepaticus 
 Caput medusae 
COMPLICATIONS: 
 Portal hypertension 
 Ascites 
 Hypersplenism 
 Variceal bleeding 
 Hepatorenal syndrome 
 Porto pulmonary hypertension 
 Hepatic encephalopathy 
 Hepatopulmonary syndrome 
 Malignant transformation. 
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DIAGNOSIS: 
Many times the presence of chronic liver disease is suggested by 
laboratory investigations. Common laboratory investigations performed 
under the label LFT (liver function tests) are 
 1) Enzyme tests 
  Serum aminotransferases (AST, ALT) 
  Serum alkaline phosphatase 
  Gamma Glutamyl Trans peptidase 
 2) Serum bilirubin 
 3) Assess synthetic function 
  Serum albumin 
  Prothrombin time and INR 
Aminotransferases: 
Both aspartate transaminase and alanine transaminase may be elevated 
but usually <3 times the upper normal limit, but can be normal in 
advanced stages of liver disease. Chronic liver disease other than alcohol 
will have AST/ALT ratio less than one. 
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Alkaline phosphatase: 
Elevated in most forms of chronic liver disease but will be less than three 
times the upper normal limit. High levels are noted in  
1) Primary biliary cirrhosis 
2) Primary sclerosing cholangitis 
Gamma Glutamyl Trans peptidase: 
It is considered moderately specific for alcoholic liver disease because of 
two reasons 
1) Alcohol induces hepatic microsomal GGT synthesis. 
2) Alcohol causes leakage of GGT from hepatocytes. 
Serum bilirubin: 
It may be normal in compensated state but elevated bilirubin indicates 
fairly advanced liver disease. 
In primary biliary cirrhosis elevated bilirubin indicates poor prognosis. 
Serum albumin: 
As liver function deteriorates albumin levels also decreases as it is solely 
synthesized in liver but hypoalbuminaemia is not specific for chronic 
liver disease as it may be decreased in other conditions like  
1) Nephrotic syndrome 
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2) Protein losing enteropathy 
3) Malnutrition 
Prothrombin time: 
Increases as liver disease progresses since coagulation factors are 
produced in liver. 
Serum globulin: 
Elevated levels of globulin are seen in cirrhosis as various antigens are 
shunted away from liver, reach systemic circulation and elicit 
immunological response. Increased levels of IgM are seen in primary 
biliary cirrhosis, increased IgA is seen in alcoholic liver disease. 
Serum sodium: 
Hyponatremia in chronic liver disease patients indicates poor prognosis, 
and is due to high levels of ADH seen in cirrhotic patients. 
Hematological investigations: 
Anemia: 
May be due to  blood loss 
   Folate deficiency 
   Direct toxicity of alcohol 
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   Hemolysis 
   Anemia of chronic disease 
   Hypersplenism 
Thrombocytopenia: 
Due to hypersplenism, but the platelet count doesn’t drop below 50000 
cells/ mm
3
. May cause bleeding if associated with coagulopathy. 
Leucopenia, neutropenia: 
Due to hypersplenism and splenic margination. 
 
INVESTIGATIONS TO DETERMINE THE ETIOLOGY OF 
CHRONIC LIVER DISEASE: 
Alcoholic liver disease: 
 History of alcohol abuse 
 AST: ALT ratio > 2 due alcohol induced deficiency of pyridoxal 
phosphate 
 Liver biopsy may show features typical of alcoholic hepatitis, 
Mallory’s hyaline, liver cell necrosis. 
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Chronic hepatitis C: 
 Anti HCV antibody 
 HCV RNA quantification 
 Liver biopsy to establish the severity of liver disease. 
Chronic hepatitis B: 
 HBsAg 
 HBeAg 
 HBV DNA Quantification 
NASH: 
 associated features of metabolic syndrome like hyperglycemia, 
hyperlipidemia. 
 Liver biopsy 
Primary biliary cirrhosis: 
 Elevated alkaline phosphatase 
 Anti-mitochondrial antibody is considered to be the hallmark of 
primary biliary cirrhosis 
 ERCP 
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Primary sclerosing cholangitis: 
 Associated with inflammatory bowel disease. 
 Contrast cholangiography shows diffuse, focal strictures and 
dilatation of bile ducts giving it a beaded appearance. 
 Anti-smooth muscle antibody (ASMA) 
 Anti-nuclear antibodies 
 Anti-neutrophilic cytoplasmic antibody(ANCA) 
Autoimmune hepatitis: 
 Increased gamma globulin levels 
 Anti-LKM1 antibody 
 Anti-ALC antibody 
Hemochromatosis: 
 Family history of cirrhosis 
 Increased skin pigmentation 
 Fasting transferrin saturation  
More than 60% in men 
More than 50 % in women 
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 Plasma ferritin  
>300mg/dl in men 
  >200mg/dl in women 
 Genetic testing  
 Liver biopsy 
Wilson’s disease: 
 Kayer Fleisher rings on slit lamp examination. 
 Decreased serum ceruloplasmin. 
 24 hour urinary copper >100mg 
 Copper content >200mg/g of liver tissue in liver biopsy. 
 Haplotype analysis. 
Alpha 1 anti-trypsin deficiency: 
 Decreased serum alpha1 anti-trypsin levels. 
 Genetic testing 
Right sided heart failure: 
 Electrocardiogram, Echocardiogram  
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RADIOLOGICAL IMAGING 
Ultrasound abdomen: 
 Provide useful information regarding liver size, echo texture. 
 Useful screening to identify development of HCC (hepatocellular 
carcinoma) in a patient with preexisting cirrhosis. 
Doppler ultrasound: 
 Provides information regarding blood flow in portal vein, hepatic 
veins. 
 Assess size of portal vein, splenic vein. 
 Identify presence of collaterals. 
Computed tomography Abdomen: 
 To assess liver size, shape. 
 To identify liver nodule. 
 To detect HCC. 
MRI Abdomen: 
 Most useful in evaluating the biliary tree 
 To detect malignancy. 
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Transient elastography
 
 (Fibro scan): 
 Noninvasive method to assess the stiffness and evaluate liver 
fibrosis and cirrhosis. 
Liver biopsy: 
 The gold standard test to aid in identifying the etiology of chronic 
liver disease. 
 To grade the disease activity. 
 To assess the severity of chronic liver disease. 
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DIAGNOSTIC ALGORITHM: CHRONIC LIVER DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
Patients with risk 
factors and/or 
clinical features of 
CLD 
Patient with 
incidental lab or 
imaging abnormality 
consistent with CLD 
Confirm CLD with 
history, physical 
examination 
Obtain LFT and targeted serology to confirm CLD 
Obtain USG Doppler to assess liver size, echo texture and 
to assess potential complication 
Refer for liver biopsy if still in doubt about diagnosis, to 
assess severity of CLD 
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 ASSESSMENT OF SEVERITY AND PROGNOSIS 
Severity may be assessed by  
1) Child Pugh’s scoring system 
2) MELD scoring system 
3) Liver biopsy 
CHILD PUGH’S SCORING SYSTEM: 
Clinical and Lab 
Criteria. 
Points 
1 2 3 
Ascites None Slight (diuretic 
responsive) 
Moderate 
(diuretic 
unresponsive) 
Albumin (g/dl) >3.5 2.8-3.5 <2.8 
Bilirubin (mg/dl) <2 2-3 >3 
Encephalopathy None Grade 1 and 2 Grade 3 and 4 
Prothrombin 
time INR 
<1.7 1.7-2.3 >2.3 
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Class A: 5-6   survival at one and two year   100% and 65%, Class B: 7-9   
survival at one and two year   80% and 60%, Class C: 10-15 survival 45% 
and 35%. 
MELD SCORING SYSTEM: 
MELD (model for end stage liver disease) was initially developed to 
assess short term prognosis in patients with chronic liver disease who 
undergo TIPS
(2,5)
 (Trans jugular intra-hepatic Porto systemic shunt) but 
its usefulness to assess the prognosis and severity of chronic liver disease 
has been well validated.It consists of three variables 
1) Serum bilirubin 
2) Serum creatinine 
3) Prothrombin time INR(International Normalized Ratio) 
SCORE THREE MONTH MORTALITY 
(%) 
>40 71.3 
30-39 52.6 
20-29 19.6 
10-19 6 
<9 5 
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MANAGEMENT OF CHRONIC LIVER DISEASE 
GENERAL MANAGEMENT
 
: 
As the patient once lands in cirrhosis, liver will never regain its normal 
structure, but symptomatic measures can go a long way in improving the 
quality of life. Liver has such a regenerative capacity that even though 
structurally abnormal its functional capacity may be achieved. 
MANAGEMENT IN A COMPENSATED STATE: 
 Adequate diet
 (6)
: 
  30-40 Kcal/kg body weight 
  1.2-1.5g of protein per kg of body weight 
 Abstinence from alcohol. 
 Weight loss if obese. 
 Early detection and treatment of complications. 
 Treatment of specific cause: 
  Antiviral therapy for chronic hepatitis B and C 
  Steroids and immunosuppressant for autoimmune hepatitis. 
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  Ursodeoxycholic acid in early stages of primary biliary 
cirrhosis. 
  Chelation therapy for Wilson’s disease. 
  Venesection for hemochromatosis. 
DECOMPENSATED STATE: 
Treatment is aimed at 
 Identification of precipitating factors 
Early detection and management of complications. 
Hepatic encephalopathy
:
 
 Avoidance of precipitating factors. 
 Lactulose 40-120 ml daily 
 Lactitol 20-40g daily 
 Rifaximin 400mg three times a day. 
 Liver transplantation. 
 
Portal hypertension:  
Propranolol 40-80 mg two times a day. 
28 
 
Ascites and peripheral edema: 
 Sodium restriction <2 g per day. 
          Fluid restriction if there is Hyponatremia. 
 Spironolactone starting dose 100 mg , maximum dose 400mg per 
day 
 Furosemide 40 mg per day, maximum 160 mg per day 
 Large volume paracentesis with intravenous salt poor albumin 
Hepatorenal syndrome: 
 Avoidance of nephrotoxins 
 Intravenous albumin 
 Midodrine 
 Octreotide 
Spontaneous bacterial peritonitis 
 Cefotaxime 2 g IV tds 
 Norfloxacin 400 mg twice daily 
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EMERGING ANTIFIBROTIC STRATEGIES: 
 The ever increasing understanding of mechanisms leading to fibro 
genesis has led to development of anti fibrotic therapy a reality in near 
future. The potential approach includes 
 Decrease and or modify host response to stellate cell activation 
 Down regulate stellate cell activation. 
 Stimulate programmed cell death of stellate cell. 
 Increase the degradation of scar matrix. 
ROLE OF LIVER TRANSPLANTATION: 
 Liver transplantation is considered when liver no longer has its 
ability to do its various functions. The following are the most common 
indication for liver transplantation 
 Hepatitis C, B 
 Alcoholic liver disease 
 Autoimmune liver disease 
 Primary biliary cirrhosis 
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MINIMAL HEPATIC ENCEPHALOPATHY 
• Minimal hepatic encephalopathy is the mild form of spectrum of 
hepatic encephalopathy. It is defined as the mild neurocognitive 
and psychomotor disorder present in patients with cirrhosis. These 
mild neurocognitive disorder primarily affects attention. Speed of 
processing information coordination motor abilities that are not 
recognizable on standard neurological examination. 
•  Zeegan et al was the first to describe this condition in 1970 when 
they discovered that 38% Of patients scored abnormal in reitan 
trailmaking test [number connection test] who had undergone 
portal decompression surgery. 
• Terminologies: previously they used the following terminologies 
for describing patients with MHE. 
1. Early HE, 
2. low-grade HE 
3. latent HE 
4. subclinical HE 
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EPIDEMIOLOGY: 
Majority of cirrhotic patients develop MHE.But there are no accurate data 
on the incidence of MHE. 
• Overt HE occurs in 30 – 50% of cirrhotic patients and in 10 – 50 % 
of patients with TIPS. 
• Prevalence of MHE has been reported to vary between 30% -84% 
in cirrhotic patients. Reasons for large variation include presence 
of prior overt HE, age, severity of liver disease, alcohol etiology, 
TIPS, surgical Porto-systemic shunts, presence of esophageal 
varices. 
PATHOGENESIS: 
The main pathogenic mechanism is increased ammonia level and an 
inflammatory response leads to swelling of astrocytes in brain, leading to 
fluid accumulation in brain and cerebral edema. 
AMMONIA: 
• Protein metabolism produces ammonia. Normally ammonia 
reaches liver where it is detoxified in urea cycle and urea is 
produced. Urea is excreted through the kidneys. 
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• In cirrhotic patients ammonia is not metabolized in liver, so it 
reaches the brain. Astrocytes are the only cells in brain that can 
metabolize ammonia.in brain ammonia combines with glutamate in 
the presence of glutamine synthetase to produce glutamine. 
GLUTAMINE IS AN OSMOLYTE. So water moves in astrocyte 
and swelling occurs leading on to cerebral edema and increased 
intracranial tension. 
• In experimental studies it was found that administration of 
methionine sulfoxemine [glutamine synthetase inhibitor] prevents 
astrocyte swelling. 
• Astrocyte swelling is compensated by release of osmolyte 
myoinositol and taurine from inside the cell. Over time the cells 
change in form and become “ALZHEIMER TYPE II” astrocytes. 
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INFLAMMATION: 
Sepsis is a common precipitating factor for decompensation of liver 
disease in previously stable patients.Serum levels of inflammatory 
markers  
• C-RP, 
• WBC count, 
• IL-6 
Were very much increased in patients with MHE, then in patients without 
MHE. 
• Once SIRS is treated these markers came to normal level and 
patients also did better in psychometric tests. TNF, IL-6  increases 
diffusion of ammonia into astrocytes. 
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NEUROSTEROIDS: 
• 18 kDa translocator protein is unregulated in microglial cells that 
are activated by inflammation. Increased expression of this 
receptor results in increased mitochondrial synthesis of 
neurosteroids. 
• Ammonia, manganese which accumulate in patients with liver 
failure act on these receptors and increases neurosteroid 
production. 
• Neurosteroids act on GABA-A receptor and enhances GABA 
nergic tone. 
36 
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OXIDATIVE AND NITROSATIVE STRESS: 
Astrocytes exposed to 
• ammonia, 
• inflammatory cytokines, 
• benzodiazepines, 
• hyponatremia 
Produce more reactive nitrogen species [RNS] and reactive oxygen 
species [ROS].Acute swelling of astrocytes occurs as astrocytes are 
exposed to ROS, RNS. Intramitochondrial ammonia mediates release 
of ROS, RNS through calcium dependent pathways. ROS is also 
involved in nitration of tyrosine residues in intracellular proteins. 
Tyrosine nitration affects the permeability of blood brain barrier and 
promotes astrocyte swelling. 
 
MANGANESE: 
• Manganese is a neurotoxin that accumulate in basal ganglia of 
patients with cirrhosis with extensive Porto caval shunts.it has been 
detected by MRI brain. Manganese induces changes in astrocytes 
of basal ganglia and promotes formation of Alzheimer type II 
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astrocytes. Manganese deposition in basal ganglia might explain 
tremors [parkinsonian symptoms] in some patients with HE. 
ZINC: 
• Zinc is a substrate of urea cycle enzymes.in cirrhotic patient’s zinc 
is depleted. Activity of ornithine transcarbamylase increases after 
zinc supplementation and this in turn lead to increased excretion of 
ammonia ions. However there is conflicting clinical data regarding 
supplementation of zinc in management of MHE. 
SEROTONIN: 
• Serotonin a neurotransmitter is important for regulation of sleep, 
locomotion and circadian rhythm. Serotonin metabolism is 
sensitive to hyperammonemia and Porto systemic shunting. This 
suggests a role for serotonin in early neuronal manifestation of HE. 
 
BRANCHED CHAIN AMMINOACIDS [BCAA] AND FALSE 
NEUROTRANSMITTERS: 
• In severe liver dysfunction there is imbalance between aromatic 
amino acids AAA [tyrosine, tryptophan and phenylalanine] and 
branched chain amioacids BCAA [leucine, isoleucine and valine]. 
In the CNS AAA and BCAA share a common transport.as a 
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consequence of increased AAA false neurotransmitters 
[phenylethanolamide and octopamide] are produced with 
subsequent development of HE. 
 
INTESTINAL FLORA: 
• Endotoxins and intestinal flora are an important link between 
ammonia, inflammation and MHE. In the study conducted by zaho 
et al, compared to healthy controls, in cirrhotic patients imbalance 
of intestinal flora has been demonstrated. They found a decrease in 
counts of bifidobacterium and an increase in counts of aerobes 
[enterobacter] and anaerobes [clostridium].in cirrhotic patients 
there has been a significant faecal overgrowth of pathogenic E.coli 
and staphylococcus species. Faecal growth of lactobacillus species 
increased after treatment with synbiotics.this was associated with 
reduction in blood ammonia and reversal of MHE in 50% of 
patients. 
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CLASSIFICATION OF HEPATIC ENCEPHALOPATHY: 
Hepatic encephalopathy is classified into 3 types by the working party at 
the 1998 world congress of gastroenterology, Vienna, Austria. 
• TYPE A 
• TYPE B 
 
• TYPE C -Type c is again divided into 3 categories. 
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DIAGNOSIS: 
• Approach to hepatic encephalopathy  comprises of 
 1.Exclusion of other causes of encephalopathy 
 2. Identification of precipitating cause 
 3. Trial of empiric treatment for HE. 
This is called as triparitite strategy. 
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RULE OUT OTHER CAUSES OF ENCEPHALOPATHY: 
 Hypoxia ,hypercapnia 
 Acidosis, uremia 
 Sensitivity to CNS drugs 
 Electrolyte changes 
 Prior seizure or stroke[post ictal confusion] 
 Delirium tremens 
 Wernicke –korsakoff syndrome 
 Intracranial hemorrhage 
 CNS sepsis 
 Cerebral edema, intracranial hypertension 
 Hypoglycemia 
 Pancreatic encephalopathy 
 Drug intoxication 
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IDENTIFICATION OF THE PRECIPITATING CAUSE OF 
HEPPATIC ENCEPHALOPATHY: 
 Sepsis 
 Gastrointestinal hemorrhage 
 Constipation 
 Dietary protein overload 
 Uremia 
 Hypokalemia 
 Alkalosis 
 Dehydration 
 Poor compliance with lactulose therapy 
 Prior anesthesia 
 Prior portal decompression procedure 
 Bowel obstruction or ileus 
 Superimposed hepatic injury 
 Development of hepatocellular carcinoma 
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INITIATING EMPPIRIC TREATMENT FOR HEPATIC 
ENCEPHALOPATHY: 
 Lactulose ,oral dose of 15-30 ml twice daily 
 Rifaximin ,oral dose of 550 mg twice daily 
 Neomycin ,oral dose of 5oo mg four times daily 
 Metronidazole, oral dose of 250 mg four times daily 
 Lactulose bowel wash 
A rapid response to this empiric treatment confirms diagnosis of HE, lack 
of response within 72 hours indicates consideration of further treatment 
options. 
DIFFERENTIAL CAUSES: 
Many conditions have similar symptoms to HE, exclusion of these 
conditions is important. 
 If there is change in mental status, SDH should be excluded as 
cirrhotic patients have coagulopathies and increased risk of falls. 
 Sepsis related organ failure, as cirrhotic patients are associated 
with an increased risk of sepsis. 
 Medication induced adverse effects. 
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Many cirrhotic patients have atleast one or multiple coexisting 
precipitating factors capable of inducing an episode of HE. 
 
DIAGNOSIS OF MINIMAL HEPATIC ENCEPHALOPATHY: 
The diagnosis of MHE is based on 
1. Confirmation of a disease that can cause MHE, such as cirrhosis or 
Porto systemic shunts. 
2. Exclusion of normal mental status on clinical examination [absence 
of clinical evidence of hepatic encephalopathy. 
3. Demonstration of abnormalities in cognition and 
neurophysiological variables 
4. Exclusion of other neurological disorders 
In cirrhotic patients a wide spectrum of neurological and 
neurophysiological abnormalities are present.it may extend from no HE, 
MHE to overt HE. 
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DIAGNOSTIC TESTS: 
Various diagnostic tests are devised to detect MHE, they are 
1. Serum ammonia 
2. Clinical scales 
        West Haven criteria 
3. Neuropsychometric tests 
      Paper and pencil tests 
      Computerized tests 
4. Electro physiologic tests 
                EEG 
               Spectral EEG 
              P300 EVOKED potentials 
             Critical flicker frequency 
5. Brain imaging 
               CT brain, 
               MRI, 
              Spectroscopy 
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SERUM AMMONIA: 
Serum ammonia levels correlate well with severity of HE. 
Routinely it is not done as it would not change the approach to 
diagnosis or in management.it is difficult to do in clinics as it has 
to be transported within 20 minutes to laboratory with ice packing. 
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CLINICAL SCALES: 
A number of scales has been discovered to diagnose HE. The first clinical 
scale was discovered by parson-smith and his colleagues in 1957.  
WEST HAVEN CRITERIA: 
This criteria is used in a number of studies. This criteria was developed in 
1977 by CONN et al. this criteria semi quantitatively grades a patients 
mental state by subjective assessment of intellectual function, behavior, 
alteration of consciousness and neuromuscular function. 
ORIGINAL VERSION: 
• Comprises of 4 grades however this scale showed substantial 
variability between observers in assessing low grades of HE. 
MODIFIED VERSION: 
•  Amodio and colleagues in 2004, proposed a modification to the 
above criteria that introduced objective scales for assessing 
individual components of the criteria. 
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CHESS: 
• Reliability of West Haven criteria can be improved by using along 
with the clinical hepatic encephalopathy staging scale [CHESS].It 
contains 9 items. 
• Minimal score = 0,maximal score = 9.this scale scores HE from 0 
[normal mental state ] to 9 [deep coma]table 3. 
Hepatic encephalopathy scoring algorithm [HESA]: 
• This was first devised by Hassanein et al.it was first used in 
multicenter study. This algorithm assess the utility of 
extracorporeal albumin dialysis in management of patients with 
HE. This is particularly useful in assessing patients with low grades 
of HE. 
NEUROPSYCOMETRIC TESTS: 
It consists of  
1. Pencil and paper tests 
2. Computerized tests. The tests should be objective, reliable, sensitive 
and valid. 
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PENCIL AND PAPER TESTS: 
These tests are employed to assess impairments in domains such as 
attention, processing speed, visuospatial functioning and response 
inhibition. 
PHES: 
Psychometric hepatic encephalopathy scoring system .this scoring is 
based on the results of hamster who used a battery of more than 20 
psychometric tests to patients with cirrhosis and controls. This test was 
designed to identify subtle cognitive changes that are characteristic of 
MHE in cirrhotic patients. Normal data for comparison was obtained 
from Germany, Italy, and Spain. 
Abnormal results strongly correlated with changes in brain imaging. This 
test was declared as the “GOLD STANDARD “ for diagnosis of MHE in 
cirrhotic patients by the working party of the 1998 world congress of 
Gastroenterology, Vienna, Austria. Due to lack of US specific normative 
data, this test failed to gain popularity in USA. This scoring comprises of  
 1.number connection test A 
 2.number connection test B 
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 3.digit symbol test 
 4.line drawing test 
 5.circle dotting test 
Impairment of more than 2SD in two or more tests is necessary for 
diagnosis of MHE. 
 
RBANS: 
Repeatable battery for the assessment of neurological status. 
This was initially used to diagnose neurocognitive disorders such as 
dementia, stroke, multiple sclerosis, traumatic brain injury and bipolar 
disorders in USA.it is effective n screening MHE.it is a paper and pencil 
test and takes 20-25 min to administer. 
• It measures working memory, visuospatial function [figure copy 
and line orientation], verbal and cognitive processing speed. 
 
COMPUTERISED PSYCOMETRIC TESTS: 
• In the last seven years a number of computerized tests have been 
developed. These tests are potential in assessing patients with HE. 
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INHIBITORY CONTROL TEST: 
This is the most popular currently available computerized test. 
This test asses 2 different cognitive domains 
 1.attention 
 2.response inhibition, 
 
Principle – based on 
                                 1. Targets 
                                 2. Lures. 
A series of different alphabet    sequences are flashed on a computer 
screen and patient is asked to respond when x is followed by y or vice 
versa-so called target. And asked not to respond when x is followed by x 
or y followed by y.-so called lure. 
A lure response more than 5 out of 40 attempts detects MHE.This test 
shows close correlations with other scores and might be approved for 
diagnosis of MHE. 
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CDR Computerized assessment system: 
This cognitive drug research system was devised to detect neurocognitive 
changes in cirrhotic patients. This test contains seven tests and measures 
continuity of attention, power of attention, quality of continuous memory, 
quality of episodic memory and speed of memory. This test shows good 
correlation with PHES. 
 
ELECTROPHYSIOLOGICAL ASSESMENTS: 
CRITICAL FLICKER FREQUENCY TEST: 
From 2002 this test is being used to asses patients with HE .this test was 
used on the principle of hepatic retinopathy. The retinal glial cells 
undergo swelling as cerebral glial cells swell in patients with HE .Light 
impulses are showed at a frequency of 60 Hz and gradually reduced by 
0.1 Hz once per second .the frequency at which light impulses are first 
perceived is the critical flicker frequency. The frequency below 39 Hz 
detects minimal hepatic encephalopathy with high specificity, sensitivity. 
This test correlates strongly with paper and pencil neuropsycometry test. 
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ELECTROENCEPHALOGRAPHY 
For research purposes this is an excellent tool for detecting hepatic 
encephalopathy. Brains electrical activity is decreased in HE. Common 
findings are increase in wave amplitude and decrease in wave frequency. 
First theta waves [4-7cps] occurs then delta waves [1-3cps] occurs. Then 
there will be loss of wave amplitude and flattening of curve occurs. This 
is mainly used for follow up examinations .clinical improvement is 
preceeded by increase in EEG frequency. This is associated with variable 
sensitivity for diagnosis of HE. Spectral EEG can be also used. 
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EVOKED POTENTIALS 
This is subdivided into exogenous and endogenous evoked 
 Potentials .exogenous evoked potentials consists of  
 1.visual evoked potentials[ VEP] 
 2.brainstem auditory evoked potentials[BAEP] 
 3. Somatosensory evoked potential. 
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These are used to assess sensory pathways. Among these BAEP is 
sensitive to diagnose HE. 
Endogenous evoked potentials asses the cognitive function P300 wave is 
commonly used in this.P300 represents stimulus evaluation processing. 
Latency –stimulation evaluation time 
Amplitude –meaning of the evoking stimulus within the experimental 
task. 
The acoustic oddball experiment is used in this.by ear phone two tones 
are randomly presented to patient ear. 
Target tone-the patient has to press the button if he hears rare tone. 
Standard tone-the patient has to ignore the button if he hears the frequent 
tone. 
In this 150 tones are presented in which 20% are target tones. During this 
process 
EEG is recorded continuously. Then separately average for target and 
standard tones. The P300 latency is prolonged in patients with HE. 
Newer advances in EEG are dominant activity and cluster analysis, 
artificial neural network expert system software and short epoch. 
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BRAIN IMAGING: 
CT brain: 
Identifies conditions that mimic or worsen HE, such as cerebrovascular 
event or Subdural hematoma.it is used for excluding other causes of 
encephalopathy. 
In most patients with HE it poorly detects low grades of cerebral edema.it 
is associated with risk of radiation exposure. 
 
MRI brain: 
Multiple techniques are available. Identifies several brain abnormalities 
associated with HE.  
 
T1-weighted imaging: 
This identifies bilateral symmetrical high intensity signal in the basal 
ganglia, due to deposition of manganese.it is identified in patients with 
cirrhosis with Porto Systemic shunts .this reverses after liver 
transplantation. 
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T2-weighted FLAIR SEQUENCE and diffusion weighted imaging: 
This identifies diffuse increase in white matter signal intensity in the 
cerebral hemispheres and the corticospinal tract .this is due to cerebral 
edema and this explains the neurologic abnormalities in cirrhotic patients. 
This reverses after liver transplantation. 
MR spectroscopy: 
This identifies increase in glutamate and glutamine signals, decrease in 
myoinositol and choline signals .homeostatic compensatory metabolic 
changes occur in the astrocyte of cirrhotic patients that prevent massive 
cerebral edema. This also resolves after liver transplantation. 
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Magnetic transfer ratio: 
This identifies mild diffuse reduction in magnetic transfer ratio in white 
matter.it reflects mild cerebral edema. These imaging modalities and 
regional cerebral blood flow changes are useful in understanding the 
pathogenic mechanisms and at present are not considered of diagnostic 
value. 
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CLINICAL SIGNIFICANCE: 
EFFECT OF MHE ON HEALTH RELATED QUALITY OF LIFE: 
MHE patients have a minimal Impairment in cognition many times. They 
have abnormalities in sleep, poor memory, impaired psychomotor 
performance and decreased attention. Activities involving these domains 
like planning a trip, driving a car are affected. These abnormalities affects 
their capacity in workplace and they have socioeconomic problems. They 
also won’t have regular employment.by using HRQoL questionnaire it 
has been found that cirrhotic patients with MHE have higher frequency of 
sleep disorders. they have unsatisfied sleep like increased daytime 
sleepiness, increased sleep latency, increased awakening episodes during 
night and decreased sleeping time .they also have defective memory. 
They are also defective in visual perception. They also have deficit in 
short term memory with relatively normal long term memory. 
EFFECT OF MHE ON DRIVING: 
In a study conducted by wein and colleagues it was found that in a 
standardized 90 minute on the road driving test 36% of cirrhotic patients 
with MHE had impairment in driving a car. Due to impaired cognition 
they are at increased risk of automobile accidents. They also had higher 
traffic rule violations.in unexpected traffic conditions they had decreased 
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speed of mental processing. Navigation is very important in driving.it is 
impaired in these patients and so they won’t have response inhibition and 
driving.it has been found that persons who perform poorly inhibitory 
control test are more prone for illegal turns and accidents. 
 
TREATMENT: 
It consists of 
 1. Pharmacologic therapy 
 2.nutritional interventions 
 3. Long term management. 
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PHARMACOLOGIC THERAPY: 
Identification of the precipitating factor and treating it helps in 
relieving the symptoms. The basic idea in treating is to decrease 
the production of ammonia and decreasing the absorption of 
ammonia. 
NON- ABSORBABLE DISACCHARIDES: 
These include lactulose and lactitol. Studies have shown that these 
agents improve cognitive function, health related quality of life and 
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sickness impact profile. This is the ‘first line’ therapy for HE. The 
oral dosage is 15 – 30 ml two times a day to produce 2 – 3 soft 
stools daily. This acts as a laxative and decreases colonic pH, 
which decreases the glutamine uptake in the gut and decreases the 
production and absorption of ammonia. 
Adverse effects: 
 Abdominal bloating 
 Hyponatremia 
 Dehydration 
 Sweet taste in the mouth. 
 
 
ANTIBIOTICS: 
Neomycin was initially used in treating HE patients. This reduces 
ammonia level by inhibiting mucosal glutaminase in the gut.it inhibits 
growth of ammoniagenic coliform bacteria. Due to safer antibiotics its 
use has declined. Its adverse effects are intestinal malabsorption, 
ototoxicity and nephrotoxicity. 
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Rifaximin is a safer antibiotic with few side effects.it was approved by 
FDA in March 2010 for treating HE. Its oral dose is 550 mg two times 
daily.in studies it was shown that remission of HE was prolonged in 
patients on rifaximin treatment. 
PREBIOTICS AND SYNBIOTICS: 
These agents decreases intestinal pH and decreases ammonia production 
and decreases portal blood ammonia levels. These synbiotics increases 
non urease producing lactobacillus species and decreases urease 
producing E.coli .patients taking probiotic yogurt a palatable food had 
showed improvement in psychometric tests .this is a effective, safe and 
long term therapy for MHE patients. This is commonly available food 
item. 
Other pharmacological agents   that can be used are zinc, bromocritine, L-
ornithine 
L-aspartate. 
 
NUTRITIONAL INTERVENTIONS: 
Skeletal muscle metabolizes ammonia.in cirrhotic patients due to lean 
body mass this path is affected and ammonia level increases in brain. 
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Cirrhotic patients should take 1.2 g/kg of protein daily that should be 
supplemented with vegetable protein and BCAA. 
BCAA: 
These amino acids improve serum albumin levels. Patients on BCAA 
recovers soon from HE, and they have increased progression free 
survival. BCAA also decreases number of hospital admissions and 
decreases the duration of stay. 
VEGETABLE BASED PROTEIN: 
Vegetable protein decreases colonic pH and decreases ammonia level.it 
has high fibre content and increases colonic motility and increases 
clearance of intestinal nitrogen. 
LONG TERM MANAGEMENT: 
OUTPATIENT MANAGEMENT: 
After patients have recovered from an episode of HE, they have to be on 
long term empiric therapy. Because this helps in good quality of life and 
recurrences can be prevented. Long term therapy mainly comprises 
lactulose and rifaximin .patients should be educated about their bowel 
movements and stool consistency and titration of lactulose .rifaximin is 
safe and patients maintaining their remission effectively. 
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SURVIVAL: 
MHE severely affects survival of cirrhotic patients. Those who are having 
poor liver function, abnormal PHES score and abnormal child Pugh score 
had poor prognosis. Patients with MHE tend to have more frequent overt 
HE. 
PROGNOSIS: 
Patients with MHE may improve, remain unchanged, deteriote or develop 
overt HE. Patients with severe liver dysfunction, abnormal PHES 
score,CFF >38,abnormal child Pugh score have more chances to develop 
overt HE. 
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PSYCOMETRIC HEPATIC ENCEPHALOPATHY SCORE: 
This includes number connection test –A, number connection test – B, 
digit symbol test [DST], Line drawing test, circle dotting test. Impairment 
of >2 SD in two or more tests is needed to diagnose minimal hepatic 
encephalopathy.  
NUMBER CONNECTION TEST – A: 
Purpose: this measures visuospatial orientation and psychomotor speed. 
Description: the subject is shown a paper with 25 numbered circles 
spread randomly. The test is to connect 1-25 as quick as possible. 
Scoring : score is the time needed to complete with error correction. 
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NUMBER CONNCTION TEST –B: 
Purpose: this measures visuospatial orientation, psychomotor speed, 
ability to shift attention. 
Description: this test contains numbers 1 – 13 and letters from A – L. 
subject is asked to connect numbers and letters in alternating manner .that 
is from 1-A-2-B-3-C and so on. 
Scoring: time needed to complete with error correction. 
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DIGIT SYMBOL TEST : 
Purpose: this measures visuo constructive abilities. 
Description: this test contains double boxes in which numbers are given 
in upper part and in the lower part the subject is to draw symbols 
pertinently. 
Scoring: result is number of boxes correctly filled within 90 seconds. 
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LINE DRAWING TEST: 
Purpose: this measures motor speed and accuracy. 
Description: the subject has to follow the route of labyrinth without 
touching the borderline and crossing. For assessing whole route is divided 
into small sections and each touching or crossing the border in a section 
is noted. 
Scoring: time needed to go through the labyrinth and number of mistakes. 
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CIRCLE DOTTING TEST: 
Purpose: tests pure motor speed. 
Description: the subject has to put a dot in each of 100 circles given on 
the sheet. 
Scoring: time needed to complete. 
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MATERIALS AND METHODS 
 
SOURCE OF DATA: 
 Patients admitted in Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai-3 
diagnosed to have Cirrhosis of liver, fulfilling the inclusion and exclusion 
criteria were included in the study group.  
SAMPLE SIZE: 
 40 cases and 40 controls 
STUDY DESIGN:  
Case – control study 
STUDY DURATION:  
6 months: March 2014-August 2014 
INCLUSION CRITERIA: 
 Age >  18 years 
 Confirmed cirrhotic patients 
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EXLUSION CRITERIA: 
Healthy volunteers Cirrhotic patients 
1.presence of 
psychiatric/neurological 
disorders 
2.consumption of 
psychotropic drugs 
3.alcohol consumption of 
>50g/d within past 3 months 
4.inability to read and write 
1.history of overt hepatic 
encephalopathy 
2.consumption of 
lactulose/psychoactive 
drugs/any antibiotics 
during the past two weeks 
3.presence of 
psychiatric/neurological 
disorders 
4.consumption of alcohol 
>50g/d within past 3 
months 
5.inability to read and write 
 
 
DATA COLLECTION AND METHODS: 
Patients have their history taken according to a questionnaire and 
subjected to clinical examination and investigations. 
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 All five tests of PHES were administered to all the enrolled 
subjects in the same sequence. The test were conducted on a one 
to one basis in a quiet room with sufficient light. 
 Liver function tests 
 Serum ammonia 
 Ultra sound abdomen 
 EEG 
 
STASTICAL METHODS APPLIED: 
Datas were analysed using the SPSS software. Statistical 
significance was indicated by the Chisquare test. Variables were 
considered to be significant if p<0.05 
 
 
 
 
 
 
  
 
 
 
 
OBSERVATION  
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RESULTS 
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OBSERVATION AND RESULTS 
 
AGE DISTRIBUTION 
 
AGE CONTROL 
GROUP 
STUDY 
GROUP 
20-30 0 2 
31-40 12 8 
41-50 16 19 
51-60 12 11 
TOTAL 40 40 
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SEX DISTRIBUTION: 
 
GROUP  MALE FEMALE TOTAL 
CONTROL COUNT 32 8 40 
%WITHIN 
GROUP 
80% 20% 100% 
%WITHIN 
SEX 
50.8% 47.1% 50% 
CASES COUNT 31 9 40 
%WITHIN 
GROUP 
77.5% 22.5% 100% 
%WITHIN 
SEX 
49.2% 52.9% 50% 
TOTAL COUNT 63 17 80 
%WITHIN 
GROUP 
78.8% 21.3% 100% 
%WITHIN 
SEX 
100% 100% 100% 
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SEX DISTRIBUTION 
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NCT – A 
 
 
GROUP NUMBER OF 
INDIVIDUALS 
MEAN SD STANDARD 
ERROR 
MEAN 
P 
value 
CONTROLS 40 65.63 9.599 1.518 0.000 
CASES 40 77.28 15.436 2.441 
 
P value <0.001 – highly significant 
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NCT – A                                    CASES 
NUMBER OF 
INDIVIDUALS 
% WITHIN THE 
GROUP 
POSITIVE  21 52.5 
NEGATIVE 19 47.5 
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NCT – A 
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NCT – B 
 
 
GROUP NUMBER OF 
INDIVIDUALS 
MEAN STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
P 
value 
CONTROLS 40 91.80 10.528 1.665 0.000 
CASES 40 115.05 35.682 5.642 
 
P value < 0.001 – highly significant 
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NCT – B                                    CASES 
NUMBER OF 
INDIVIDUALS 
% WITHIN THE 
GROUP 
POSITIVE  26 65 
NEGATIVE 14 35 
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NCT – B 
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DST 
 
 
GROUP NUMBER OF 
INDIVIDUALS 
MEAN STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
P 
value 
CONTROLS 40 24.65 4.389 0.694 0.000 
CASES 40 17.83 5.879 0.929 
 
P value < 0.001 – highly significant 
 
 
 
DST                                    CASES 
NUMBER OF 
INDIVIDUALS 
% WITHIN THE 
GROUP 
POSITIVE  40 100 
NEGATIVE 0 0 
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DST 
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LDT: 
 
 
GROUP NUMBER OF 
INDIVIDUALS 
MEAN STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
P 
value 
CONTROLS 40 64.03 10.154 1.605 0.000 
CASES 40 76.83 15.387 2.433 
 
P value <0.001 – highly significant 
 
 
 
LDT                                    CASES 
NUMBER OF 
INDIVIDUALS 
% WITHIN THE 
GROUP 
POSITIVE  27 67.5 
NEGATIVE 13 32.5 
 
92 
 
 
 
LDT 
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CDT: 
 
 
GROUP NUMBER OF 
INDIVIDUALS 
MEAN STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
P 
value 
CONTROLS 40 66.47 8.910 1.409 0.000 
CASES 40 79.83 16.175 2.558 
 
P value <0.001 – highly significant 
 
 
 
CDT                                    CASES 
NUMBER OF 
INDIVIDUALS 
% WITHIN THE 
GROUP 
POSITIVE  24 60 
NEGATIVE 16 40 
94 
 
 
 
 
CDT 
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PHES: 
 
GROUP  CONTROL CASES TOTAL 
POSITIVE COUNT 2 19 21 
%WITHIN 
PHES 
POSITIVE 
9.5% 90.5% 100% 
%WITHIN 
GROUP 
5% 47.5% 26.3% 
NEGATIVE COUNT 38 21 59 
%WITHIN 
PHES 
POSITIVE 
64.4% 35.6% 100% 
%WITHIN 
GROUP 
95% 52.5% 73.8% 
TOTAL COUNT 40 40 80 
%WITHIN 
PHES 
POSITIVE 
50% 50% 100% 
%WITHIN 
GROUP 
100% 100% 100% 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
18.660(b) 1 .000     
Continuity 
Correction(a) 
16.529 1 .000     
Likelihood Ratio 20.872 1 .000     
Fisher's Exact 
Test 
      .000 .000 
Linear-by-Linear 
Association 
18.427 1 .000     
N of Valid Cases 80         
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USG ASCITES WITH MHE PHES: 
 
 
USG                              MHE - PHES 
POSITIVE NEGATIVE 
 
 
 
 
ASCITES 
PRESENT 11 2 
ABSENT 8 19 
TOTAL 19 21 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
10.639(b) 1 .001     
Continuity 
Correction(a) 
8.548 1 .003     
Likelihood 
Ratio 
11.374 1 .001     
Fisher's Exact 
Test 
      .002 .001 
Linear-by-
Linear 
Association 
10.373 1 .001     
N of Valid 
Cases 
40         
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BILIRUBIN AND AMMONIA LEVLES WITH PHES- MHE: 
 
 
 MHE 
NUMBER  
OF 
INDIVIDUALS Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
value 
T.BILIRUBIN Positive 
19 5.405 3.1914 .7322 
0.001 
  Negative 
21 2.681 .7387 .1612 
AMMONIA Positive 
19 93.47 14.615 3.353 
0.000 
  Negative 
21 78.05 7.652 1.670 
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EEG WITH PHES -MHE: 
 
 
                    EEG PHES 
POSITIVE 
PHES 
NEGATIVE 
TOTAL 
SUGGESTIVE COUNT 3 0 3 
%WITHIN 
EEG 
POSITIVE 
100% 0% 100% 
%WITHIN 
PHES 
POSITIVE 
15.8% 0% 7.5% 
NOT 
SUGGESTIVE 
COUNT 16 21 37 
%WITHIN 
EEG 
POSITIVE 
43.2% 56.8% 100% 
%WITHIN 
PHES 
POSITIVE 
84.2% 100% 92.5% 
TOTAL COUNT 19 21 40 
%WITHIN 
EEG 
POSITIVE 
47.5% 52.5% 100% 
%WITHIN 
PHES 
POSITIVE 
100% 100% 100% 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
3.585(b) 1 .058     
Continuity 
Correction(a) 
1.670 1 .196     
Likelihood Ratio 4.737 1 .030     
Fisher's Exact 
Test 
      .098 .098 
Linear-by-Linear 
Association 
3.495 1 .062     
N of Valid Cases 40         
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RESULTS 
 
 In our study mean age of controls is 45.3,mean age of cases is 
45.28.from 20 to 30 years no controls ,2 cases present,from 31 to 
40 -12  subjects were controls,8 patients were cases,from 41 to 50 
years 16 were controls,19 were cases.from 51 to 60 years 12 were 
controls,11 were  cases.p value was 0.987,so age wise no 
significant difference present. 
 In our study in  controls 32 males and 8 females were present,in 
cases 31 males and 9 females were present.p value is 0.785.so 
statistically not significant. 
 In NCT-A 21 cases were PHES positive, 19 were PHES 
negative.the mean value in controls were 65.63 and in cases were 
77.28. 
 In NCT-B 26 cases were PHES positive,14 were PHES 
negative.the mean value in controls was 91.80 and in cases was 
115.05. 
 In DST 40 CASES WERE PHES positive,no cases were PHES 
negative.the mean value in controls is  24.65,in cases were 17.83. 
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 In LDT 27cases were PHES positive,13 cases were PHES 
negative.the mean value in controls was 64.03 and in cases were 
76.83. 
 In CDT 24 cases were PHES positive and 16 cases were PHES 
negative. The mean value in controls 66.47 and in cases was 79.83. 
 From this PHES is positive in 19 cases and in 2 controls .PHES 
negative in 21 cases and 38 controls.p value is <0.001.so MHE is 
present in 19 cases [47.5%] out of 40. 
 Out of these 19 cases ascites was detected in 11 cases.so chances of 
MHE is more common in decompensated liver disease. 
 Out of the 40 cases bilirubin was more than 5.405 and ammonia 
was more   than 93 microgram/dl in 19 cases and bilirubin was less 
than 2.681 in 21 cases. ammonia was less than 78 micrograms/dl in 
21 cases. 
 Out of these 19 cases EEG changes was observed in only 3 cases, 
so EEG does not help to detect patients with MHE.it can be used as 
follow up tool. 
 
 
  
 
 
 
 
DISCUSSION 
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DISCUSSION 
 
Number of patients taken up for study: 
Study groups             total number of controls, cases 
Seo YS et al                                           200    160 
Su Wen li et al                                      146        53        
Present study                                           40      40 
 
AGE: 
The mean age of controls and cases are 
Seo YS et al        41+13, 55+8 
Su Wen li et al    37.3+10.5, 45.6+8.2 
Present study      45.30, 45.28. 
The mean age of controls was higher than previous studies and the mean 
age of cases was parallel to previous studies. 
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SEX DISTRIBUTION : 
The sex distribution in the studies are 
Seo YS et al    100 [50%] men were controls, 102[63.8%] men were 
cases, 
Su Wen li et al 99 [67.8%] men were controls, 50[94.3%] men were 
cases, 
Present study 32[80.0%] men were controls, 31[77.5%] men were cases. 
 
PHES SCORE: 
By applying PHES score, MHE was diagnosed in 
41 patients [25.6%] by Seo YS et al 
26 patients [49.1%] by Su Wen li et al  
19 patients [47.5%] In present study. 
 
CORRELATION WITH SEVERITY OF LIVER DISEASE: 
In the study by Su Wen li et al, cases with child Pugh B, C had a higher 
proportion of PHES positivity, MHE. In the present study cases with 
ascites had a higher proportion of PHES positivity.so PHES correlates 
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well with decompensated liver disease. And decompensated liver disease 
patients are more prone for MHE.  
 
CORRELATION WITH SERUM AMMONIA: 
In the study done by Su Wen li et al serum ammonia was done in 26 
cirrhotic patients and was found to be similar between MHE and non 
MHE groups.in the study done by Roxana et al, serum ammonia level 
increased significantly in cirrhotic patients after oral glutamine compared 
to control group.In the present study serum ammonia level is increased in 
19 cases. 
So from the present study, PHES score is statistically significant in 
detecting MHE in cirrhotic patients. Patients with severe liver disease 
with ascites, increased ammonia had high PHES positivity.  
 
CORRELATION WITH EEG : 
In our stud EEG changes were seen in only 3 patients with PHES 
positive, so EEG is not effective in detecting MHE.EEG can be used for 
follow up of patients with hepatic encephalopathy. 
 
  
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
107 
 
CONCLUSION 
 
 PHES score is statistically significant in detecting minimal hepatic 
encephalopathy in cirrhotic patients. 
 Incidence of MHE is more with severe liver dysfunction. 
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ANNEXURES 
 
 
 
 
 
 
 
“PSYCHOMETRIC HEPATIC ENCEPHALOPATHY SCORE 
FOR THE DETECTION OF MINIMAL HEPATIC 
ENCEPHALOPATHY IN SOUTH INDIAN PATIENTS WITH 
LIVER CIRRHOSIS” 
 
PROFORMA 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
 
CONTACT NUMBER  : 
COMPLAINTS   : 
 
 
PAST HISTORY   : 
 
 
TREATMENT HISTORY : 
GENERAL EXAMINATION : 
 
 
VITALS     : 
 SYSTEMIC EXAMINATION 
 
CENTRAL NERVOUS SYSTEM: 
 
ABDOMEN                                  : 
 
CARDIOVASCULAR SYSTEM: 
  
RESPIRATORY SYSTEM         : 
LIVER FUNCTION TESTS: 
ULTRASONOGRAM OF ABDOMEN: 
PHES: 
SERUM AMMONIA: 
EEG: 
 
 
 
 
 
 
 
 
 INFORMATION SHEET 
We are conducting a study on “PSYCHOMETRIC HEPATIC 
ENCEPHALOPATHY SCORE FOR THE DETECTION OF 
MINIMAL HEPATIC ENCEPHALOPATHY IN SOUTH INDIAN 
PATIENTS WITH LIVER CIRRHOSIS” among patients attending 
Rajiv Gandhi Government General Hospital, Chennai. 
The purpose of this study is to standardize the PHES in healthy 
south Indian population and evaluate the prevalence of MHE among 
south Indian patients with liver cirrhosis 
In this study we will be performing number connection test, A, B, 
Line drawing test, Digit symbol test, Circle dot test. For this test we will 
be providing paper and pen. This test is done to assess the motor speed, 
accuracy, concentration, attention and memory.   
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
Signature of Investigator 
 
Date : 
Place : 
 
Signature of Participant
MuhŒ¢á jftš jhŸ 
br‹id ïuhé›fhªâ muR bghJ kU¤Jtid¡F tU« 
nehahËfË‹ fšäuš RU§»a ÃiyÆš tU« bj‹Åªâa 
nehahËfS¡F V‰gL« btË¥gilahf bjÇahj Mu«gfhy _is ghâ¥ò 
nehÆid PHES _y« f©l¿jš g‰¿a MuhŒ¢á eilbgW»wJ. 
Ú§fS« ïªj MuhŒ¢áÆš g§nf‰f eh§fŸ ÉU«ò»nwh«. PHES 
brŒKiw _y« nehahËfis MuhŒ¢á brŒJ mj‹ _y« »il¡F« 
kâ¥ÕLfis MuhŒnth«. 
ïªj MuhŒ¢áÆš number connection test, A, B, Line drawing 
test, Digit symbol test, Circle dot test bfhL¡f¥gL«. c§fS¡F 
ngdhî«, ng¥gU« bfhL¡f¥gL«. ïªj gÆ‰á _y« c§fË‹ ò¤â¡ 
T®ik, ntf¤ j‹ik k‰W« Phgf r¡â f©l¿a¥gL«. 
ïªj MuhŒ¢áÆ‹ Koîfis mšyJ fU¤J¡fis btËÆL«nghnjh 
mšyJ MuhŒ¢áÆ‹nghnjh j§fsJ bgaiunah mšyJ milahs§fisnah 
btËÆl kh£nlh« v‹gij bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj MuhŒ¢áÆš g§nf‰gJ j§fSila ÉU¥g¤â‹ngÇšjh‹ 
ïU¡»wJ. nkY« Ú§fŸ vªj neuK« ïªj MuhŒ¢áÆÈUªJ ã‹th§fyh« 
v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«. 
ïªj MuhŒ¢áÆ‹ Koîfis MuhŒ¢á‹ nghJ mšyJ MuhŒ¢á‹ 
KoÉ‹ nghJ j§fS¡F m¿É¡f¥gL« v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«. 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu§fŸ vd¡F És¡f¥g£lJ. 
v‹Dila rªnj§fis nf£fî«, mj‰fhd jFªj És¡f§fis bgwî« 
thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahf¤jh‹ g§nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹. 
 
 
MuhŒ¢áahs® ifbah¥g«   g§nf‰ghs® ifbah¥g« 
ehŸ  : 
ïl« : 
 
 
  
 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
“PSYCHOMETRIC HEPATIC ENCEPHALOPATHY SCORE FOR THE DETECTION OF MINIMAL HEPATIC 
ENCEPHALOPATHY IN SOUTH INDIAN PATIENTS WITH LIVER CIRRHOSIS” 
MASTER CHART 
Controls  
S.NO AGE SEX 
NCT-A 
(sec) 
NCT-B 
(sec) 
DST 
(box) 
LDT 
(sec) 
CDT 
(sec) 
1 41 M 66 102 27 54 50 
2 58 M 74 80 32 62 66 
3 47 M 42 92 26 42 74 
4 52 M 76 100 36 76 73 
5 55 F 53 96 22 53 60 
6 49 M 44 104 24 49 69 
7 38 M 62 86 32 62 42 
8 56 M 66 93 20 66 72 
9 39 F 78 120 22 78 69 
10 44 F 72 76 28 72 55 
11 48 M 69 88 24 66 68 
12 52 M 70 104 26 69 63 
13 46 M 63 110 22 63 75 
14 36 M 66 92 24 70 66 
15 42 F 73 78 20 66 72 
16 57 M 76 86 19 73 54 
17 41 M 71 84 24 76 56 
18 52 M 68 96 26 71 69 
19 46 M 64 104 22 68 44 
20 38 M 74 102 29 64 73 
21 35 M 76 86 19 74 76 
22 53 M 73 88 20 76 74 
23 44 F 69 92 22 73 79 
24 41 M 44 96 19 69 68 
25 56 M 56 76 26 47 65 
26 51 M 59 82 25 56 74 
27 38 M 72 86 22 47 76 
28 48 M 66 92 23 56 65 
29 36 M 63 101 19 44 68 
30 39 M 65 88 24 72 72 
31 45 F 73 86 30 66 63 
32 52 M 68 94 32 63 70 
33 37 M 55 76 25 65 69 
34 48 M 69 82 19 73 72 
35 38 F 72 90 30 68 78 
36 47 M 43 110 32 55 66 
37 52 M 60 89 19 69 62 
38 37 M 69 104 24 72 54 
39 36 F 72 76 26 43 76 
40 42 M 74 85 25 73 62 
 
 
 
 
 
 
MASTER CHART - CASES:  
S.NO AGE SEX 
NCT-A  
(sec) 
NCT-B 
(sec) 
DST 
(box) 
LDT 
(sec) 
CDT 
(sec) 
USG 
(ASCITES) 
TOTAL 
BILIRUBIN 
mg/dL 
AMMONIA 
µgm/dL EEG 
1 53 M 68 110 22 56 88 no evidence 2.4 74 not suggestive 
2 45 M 94 103 11 62 76 no evidence 3.6 72 not suggestive 
3 56 F 56 142 14 68 102 present 8.6 104 not suggestive 
4 38 M 62 88 18 66 98 no evidence 2.5 83 not suggestive 
5 43 M 72 102 14 68 76 no evidence 2.6 81 not suggestive 
6 48 M 102 152 12 93 88 present 5.6 98 suggestive 
7 52 M 56 110 12 74 112 present 4.6 96 not suggestive 
8 38 F 68 98 32 68 84 no evidence 3.6 68 not suggestive 
9 42 F 90 86 24 72 86 no evidence 2.8 72 not suggestive 
10 55 M 96 153 10 106 88 present 7.2 107 not suggestive 
11 36 M 76 96 28 84 76 no evidence 2.6 81 not suggestive 
12 28 M 98 166 10 88 74 present 12.8 93 not suggestive 
13 45 M 65 149 22 96 57 no evidence 3.6 69 not suggestive 
14 38 F 56 98 24 66 68 no evidence 3.9 74 not suggestive 
15 47 M 98 164 8 92 68 no evidence 10.7 118 not suggestive 
16 49 M 112 163 20 72 72 present 8.8 93 suggestive 
17 52 M 72 172 13 112 98 present 6.9 116 not suggestive 
18 35 M 68 98 16 98 103 no evidence 3.5 99 not suggestive 
19 46 M 66 84 14 68 72 no evidence 2.8 84 not suggestive 
20 48 M 96 162 11 88 74 present 6.8 95 not suggestive 
21 44 M 88 98 16 56 62 present 3.2 93 not suggestive 
22 49 M 84 88 11 64 99 no evidence 2.5 83 not suggestive 
23 37 F 102 162 19 86 86 present 4.8 106 not suggestive 
24 52 F 72 152 22 76 72 no evidence 1.9 73 not suggestive 
25 56 M 76 78 21 98 66 no evidence 1.6 75 not suggestive 
26 55 M 64 86 23 67 68 no evidence 2.4 81 not suggestive 
27 43 M 68 94 24 49 68 no evidence 2.6 67 not suggestive 
28 46 M 98 173 12 103 92 present 5.9 96 not suggestive 
29 38 M 76 112 26 92 104 no evidence 1.8 72 not suggestive 
30 56 M 88 148 12 72 124 present 4.2 103 not suggestive 
31 43 M 76 98 19 67 86 no evidence 1.8 81 not suggestive 
32 48 M 72 87 13 63 72 no evidence 2.8 73 not suggestive 
33 38 F 66 76 22 82 68 no evidence 2.2 76 not suggestive 
34 51 M 68 66 19 76 62 no evidence 1.8 82 not suggestive 
35 49 M 92 182 10 74 89 present 2.8 96 suggestive 
36 28 M 86 66 23 83 68 no evidence 1.7 86 not suggestive 
37 43 M 56 82 24 88 56 no evidence 2.5 73 not suggestive 
38 46 F 58 98 19 59 72 no evidence 2.4 76 not suggestive 
39 51 F 62 62 22 62 57 no evidence 2.4 77 not suggestive 
40 44 M 68 98 21 59 62 no evidence 1.8 69 not suggestive 
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